Rezolute Presents RZ358 Clinical Data-Validated Model of the Pharmacokinetics and Glycemic Response in Congenital Hyperinsulinism ...
REDWOOD CITY, Calif., June 01, 2020 (GLOBE NEWSWIRE) -- Rezolute, Inc. (“Rezolute” or “the Company”) (OCTQB:RZLT) recently announced that it has validated pharmacokinetic (PK) and pharmacodynamic (PD) models of its lead clinical asset, RZ358. Phase 2a data …